Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (9)	10/30/1998 10:40:00 AM
From: Richard Huth	Read Replies (1) \| Respond to of 1386

Even if this might look promising, I would not concentrate myself on this subjects. It would be a nice-to-have product for PARS, but what's about trials? Would you like to be a volunteer? -I wouldn't ;-) I think we should not put too much hope in maybe-products that might come in 6-8 years or not. What is going to drive the stock price are the well known figures: (hopefully) speeding up sales of Lotemax and Alrex,announcing the co-marketing partner for both products and finding a partner for Ph/III for Hu-211 without any delays (signing a contract can become a difficult and time consuming subject). I doubt that any of the early stage hopes will have an impact on prices. Only promising details for HU211 in stroke could drive the stock. -Richard